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The ability of glucagon (10 nM) to increase hepatocyte intracellular cyclic AMP concentrations was 
reduced markedly by the tumour-promoting phorbol ester TPA (12-0-tetradecanoyl phorbol-13-acetate). 
The half-maximal inhibitory effect occurred at 0.14 ng/ml TPA. This action occurred in the presence of 
the cyclic AMP phosphodiesterase inhibitor isobutylmethylxanthine (1 mM) indicating that TPA inhibited 
glucagon-stimulated adenylate cyclase activity. TPA did not affect either the binding of glucagon to its 
receptor or ATP concentrations within the cell. TPA did inhibit the increase in intracellular cyclic AMP 
initiated by the action of cholera toxin (1 pg/ml) under conditions where phosphodiesterase activity was 
blocked. TPA did not inhibit glucagon-stimulated adenylate cyclase activity in a broken plasma membrane 
preparation unless Ca’+, phosphatidylserine and ATP were also present. It is suggested that TPA exerts 
its inhibitory effect on adenylate cyclase through the action of protein kinase C. This action is presumed 
to be exerted at the point of regulation of adenylate cyclase by guanine nucleotides. 
Protein kinase C Guanine nucleotide regulation Tumor promoter Adenylate cycIase 
Phorbol ester 
1. INTRODUCTION 
TPA (12-0-tetradecanoyl phorbol-13-acetate) is
one of the most potent tumour promoters that is 
known to date [ 1,2]. It binds specifically with high 
affinity to cell surface receptors [3,4], inducing 
pleiotropic and reversible effects on cell structure 
and function (see [1,4]). Recently, the exciting 
observation was made that the so-called phorbol 
ester receptors are associated with the activation of 
protein kinase C [7,8]. This enzyme appears to oc- 
cur universally in eukaryotes [7] and may be the 
route whereby phorbol esters exert at least some of 
their effects on target cells [6,8]. 
Hormones, such as glucagon, activate adenylate 
cyclase through a well-elucidated mechanism. 
Thus, glucagon binds with high affinity to recep- 
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tors on the hepatocyte surface, whereupon 
adenylate cyclase becomes activated, giving rise to 
a rapid and dramatic increase in intracellular cyclic 
AMP concentrations (see [9]). This involves the oc- 
cupied hormone receptor activating a distinct 
guanine nucleotide regulatory protein, called N,, 
which subsequently interacts with, and activates, 
the catalytic unit of adenylate cyclase (see [lo]). 
Alterations in intracellular cyclic AMP concentra- 
tions have been observed in transformed cells, and 
proposed to exert effects on cell growth and 
development [9,10]. Here we use the glucagon- 
stimulated adenylate cyclase activity from 
hepatocytes, as a model system, to show that the 
phorbol ester, TPA, can inhibit adenylate cyclase 
activity. 
2. MATERIALS AND METHODS 
Hepatocytes, from male Sprague-Dawley rats 
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(200-300 g) were prepared and incubated as in [9]. 3. RESULTS AND DISCUSSION 
A membrane fraction was obtained from these 
hepatocytes as in [13] and used for the assay of 
adenylate cyclase activity. This membrane 
preparation was assayed for adenylate cyclase ac- 
tivity basically as described by us in [14]. Briefly 
the incubation mixture contained final concentra- 
tions of 1.5 mM ATP, 5 mM MgS04, 10 mM 
theophylline, 7.4 mg/ml phosphocreatine, 1 mg/ 
ml creatine kinase and 25 mM triethanolamine. 
HCl at a final pH of 7.4. Membranes were present 
at 1 mg/ml and rates were determined from linear 
time courses obtained over 10 min incubation at 
30°C. Measurement of cyclic AMP produced was 
performed as described by us in [14]. 
To assess intracellular cyclic AMP accumula- 
tion, cells (4-5 mg dry wt/ml) were pre-incubated 
for 20 min at 37°C with isobutylmethylxanthine 
(10 mM), to inhibit cyclic AMP phosphodiester- 
ases (see [9]). After an appropriate period of in- 
cubation, aliquots were taken for the determina- 
tion of intracellular cyclic AMP content as describ- 
ed by us in [15]. 
The specific binding of ‘251-labelled glucagon to 
the intact hepatocytes was measured essentially as 
in [ 161 except that the cells were separated from the 
incubation medium by centrifugation through 
bromododecane for 1 min at 400 x g. Non-specific 
binding was assessed by the inclusion of unlabelled 
glucagon (10 PM) in the incubation medium. 
Rat liver plasma membranes from male, 
Sprague Dawley rats were isolated and purified as 
before [ 14,171. Adenylate cyclase activity in these 
purified membranes was assessed essentially as in 
u41. Here, incubation mixtures contained 
glucagon (10 nM), GTP (lOpM), CaC12 (50pM), 
a sonicated dispersion of phosphatidylserine 
(20pg/ml), ATP (1.5 mM), MgS04 (1 mM), 
theophylline (10 mM), phosphocreatine (7.4 mg/ 
ml), creatine kinase (1 mg/ml) and triethanol- 
amine. HCl (25 mM) at a final pH of 7.4 plus 
membranes (500 /cg/ml). Linear time courses over 
10 min at 30°C were obtained under all assay con- 
ditions. TPA was freshly prepared dissolved in 
DMSO at 1 mg/ml so that the DMSO concentra- 
tion in the assay was always < 0.001%. Incubation 
mixtures were always freshly prepared on the day 
of use. Controls also had the appropriate DMSO 
content. 
When intact hepatocytes were challenged with 
glucagon (10 nM), intracellular cyclic AMP con- 
centrations rose from around 2 + 0.5 to 84.0 f 
4.5 pmol/mg dry wt cells after 5 min (SE, n = 3). 
Such experiments were performed in the presence 
of the cyclic AMP phosphodiesterase inhibitor, 
isobutylmethylxanthine at concentrations (1 mM) 
which blocked the breakdown of cyclic AMP in 
hepatocytes [9]. If the cells were pre-treated with 
the phorbol ester TPA, prior to challenge with 
glucagon (10 nM), this increase in intracellular 
cyclic AMP was reduced markedly (fig.la). The 
half-maximal inhibitory effect (IDSO) occurred at 
0.14 + 0.02 ng TPA/ml (SE, n = 3), which is 
within the range where TPA is believed to elicit its 
biological effects, including its promotional activi- 
ty [ 1,4,6]. We noted that the non-promoting 
analogue of TPA, 4-0-methyl-TPA [18] exerted 
no such inhibitory effect on cyclic AMP accumula- 
tion. The effect of TPA must therefore be to in- 
hibit cyclic AMP production as under these condi- 
tions cellular cyclic AMP phosphodiesterase activi- 
ty was blocked [9] and no TPA-induced increase in 
extracellular cyclic AMP was observed (unpub- 
lished). We also observed (fig.1) that 1251-labelled 
glucagon specific binding was unaffected, in- 
dicating that TPA either inhibited the catalytic unit 
of adenylate cyclase per se or the functioning of 
the guanine nucleotide regulatory protein (N,) 
which effects the cholera toxin and the hormone- 
receptor mediated stimulation of adenylate cyclase 
(see [lo]). The functioning of adenylate cyclase 
was not altered by any change in substrate concen- 
tration as intraeellular ATP concentrations were 
9.54 + 0.21 nmol/mg dry wt cells in control ex- 
periments and 9.38 f 0.21 nmol/mg dry wt in cells 
treated for 20 min with 10 ng/mg TPA (n = 4, 
SE). 
Cholera toxin can increase intracellular cyclic 
AMP concentrations by causing the ADP- 
ribosylation of N,, which subsequently activates 
adenylate cyclase [lo]. After 30 min incubation of 
hepatocytes at 37°C with cholera toxin (1 /rg/ml) 
in the presence of isobutylmethylxanthine (1 mM), 
to inhibit cyclic AMP phosphodiesterase (see [9]), 
intracellular cyclic AMP concentrations had risen 
to 82 rf: 4 pmol cyclic AMP/mg dry wt cells. If, 
however, the cells were treated with 1 ng TPA/ml, 
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Fig.1. The effect of TPA on glucagon binding to 
hepatocytes and on the glucagon-stimulated adenylate 
cyclase activity in intact hepatocytes and purified plasma 
membranes. (a) Action of TPA on the specific “‘I- 
labelled glucagon binding to intact hepatocytes (0); 
change in intracellular concentrations of cyclic AMP in 
hepatocytes treated with either TPA (0) or 40methyl- 
TPA (A). These ligands were added to the intact 
hepatocytes, as per the diagram, and incubation 
continued for a further 10 min. The cells were then 
challenged with glucagon (10 nM) and after 10 min 
harvested and their intracellular cyclic AMP content 
determined. The mean of 4 experiments (n = 4) using 
different hepatocyte preparations is shown (errors are 
SE) with triplicate determinations of cyclic AMP. (b) 
Action of TPA on the glucagon-stimulated adenylate 
cyclase activity of isolated, purified rat liver plasma 
membranes. The specific activity of the purified 
membranes was 58.6 + 11.6 pmol/min per mg protein 
for 3 different membrane preparations (errors are SD). 
We found it crucial that assay mixtures were freshly 
prepared each day and plasma membranes were stored at 
- 80°C. 
then cyclic AMP concentrations rose to only some 
45 + 4.5 pmol cyclic AMP/mg dry wt after ex- 
posure to cholera toxin (n = 4, SE). As TPA clear- 
ly cussed inhibition of cyclic AMP accumulation, 
under conditions where phosphodiesterase activity 
was blocked, then its site of action does not appear 
to be at the level of receptor-N, coupling but would 
seem to occur either at the catalytic unit of 
adenylate cyclase itself or at the level of N,- 
adenylate cyclase coupling. This is supported by 
our observation that not only is the activity of 
glucagon-stimulated adenylate cyclase inhibited in 
membranes prepared from TPA-treated cells, but 
so also is the stimulation achieved by the non- 
hydrolysable GTP analogue p[NH]ppG, which 
acts to stimulate adenylate cyclase through N,. In- 
deed, the action of TPA would appear to be ex- 
erted at the level of regulation by guanine 
nucleotides as basal adenylate cyclase activity, 
presumably a measure of the functioning of the 
catalytic unit itself, was unchanged in membranes 
from TPA-treated cells (table 1). 
In a number of instances [191, inhibitory effects 
exerted on adenylate cyclase through receptor- 
coupled systems have been shown to be exerted 
through a distinct type of inhibitory guanine 
nucleotide regulatory protein (Ni). We, however, 
Table 1 
The adenylate cyclase activity of membranes from TPA- 
treated hepatocytes 
Activated 
state 
Specific activity % Inhibition 
in control of adenylate 
membranes cyclase in 
membranes from 
TPA-treated cells 
Basal 0.79 + 0.21 7+8 
PWHIPPG 10.9 f 2.8 22 z!z 1.5 
Glucagon + GTP 25.0 f 2.6 31 + 5.0 
Hepatocytes were incubated as in [9] for 15 min at 37°C 
with TPA (10 ng/ml) after which a membrane fraction 
was prepared as in [13]. The appropriate stimulatory 
ligand was also present as per the table. In this instance 
GTP was added at 100,~M, glucagon at 10 nM and 
guanosine 5’-v,y-imidoltriphosphate (p[NH]ppG) at 
100 FM. Errors are SE from 3 separate xperiments (n = 
3) using different hepatocyte preparations. Adenylate 
cyclase assays were performed in triplicate in each 
instance 
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consider it extremely unlikely that TPA acts 
through Ni. Firstly, the effects of TPA are not 
blocked by islet activating protein from Bordatella 
pertussis (unpublished) which prevents the func- 
tioning of Ni [20]. Secondly, to observe inhibition 
of hormone-stimulated activity in a broken mem- 
brane system much higher GTP concentrations are 
required [19] than were used here (table 1) and 
thirdly, inhibitory effects exerted through Ni are 
not observed in broken membranes under condi- 
tions of high p[NH]ppG concentrations [19] such 
as have been employed in this study (table 1). It is 
possible, therefore, that TPA exerts its effects at 
the level of the stimulatory guanine nucleotide 
regulatory protein, N,. 
Stimulatory and inhibitory hormones acting 
upon adenylate cyclase will exert their effects in 
broken membrane systems [10,191. In contrast, the 
addition of TPA to purified rat liver plasma mem- 
branes failed to exert any effect on adenylate 
cyclase activity (fig.2). This suggests that TPA is 
affecting adenylate cyclase through a novel 
mechanism. 
Recently it was demonstrated that TPA can 
stimulate the phospholipid and Ca2+-dependent 
protein kinase C (see [8]) which may be an integral 
part of the phorbol ester receptor itself [21]. Here 
we see that using purified liver plasma membranes, 
which have been shown to exhibit protein kinase C 
activity [22], then TPA will indeed inhibit 
glucagon-stimulated adenylate cyclase provided 
that both Ca2+ and phosphatidylserine are present 
in the incubation mixture (fig.2). The inhibition of 
adenylate cyclase caused by TPA is dose dependent 
(fig.lb) with an IDSO of 0.21 -t 0.09 ng TPA/ml 
(n = 3 with different membrane preparations, SE). 
This paralleled that observed in the intact cell 
(fig.la), although the magnitude of the inhibition 
appeared to be somewhat less. As protein kinase C 
is found in both soluble and particulate fractions 
and TPA is believed to cause the recruitment of ad- 
ditional enzyme to the plasma membrane fraction 
[23], then this may have enhanced the response to 
TPA in the intact cell. Such an inhibitory effect 
was not observed with 4-0-methyl-TPA, the non- 
promoter analogue of TPA (unpublished) yet was 
mimicked, to a somewhat lesser degree, with 
diolein which also activates protein kinase C 
(fig.2). The effect on adenylate cyclase would ap- 
pear to involve phosphorylation as no inhibition 
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Fig.2. The inhibitory action of TPA and diolein on the 
glucagon-stimulated adenylate cyclase activity of 
purified plasma membranes is dependent upon Ca2+ and 
phosphatidylserine. The (glucagon + GTP)-stimulated 
adenylate cyclase activity of purified rat liver plasma was 
measured as described in section 2 except that additions 
of CaC12 (50 pM), phosphatidylserine (PS, 20 fig/ml), 
TPA (10 ng/ml) and diolein (0.5 pg/ml) were only made 
as and when indicated. Rates were obtained from linear 
time courses over 10 min at 30°C. If the concentration 
of Mg’+ was elevated to 5 mM, rather than being at 
1 mM, then the inhibitory effects were reduced by about 
50%. Errors are SD for 3 experiments (n = 3) using 
different membrane preparations where adenylate 
cyclase activity was assessed in triplicate. In each 
instance activities were expressed as a percentage of their 
appropriate control activity. The specific activity of 
these membranes is as in the legend to fig.lb. Data are 
expressed as percentage inhibition to enable comparison. 
This is particularly important as, under these conditions, 
Ca2+ itself causes a substantial inhibition of adenylate 
cyclase activity in the assay (see [24]). All solutions were 
prepared fresh each day. 
(<4%, n = 3) occurred if ATP[y-S], which can be 
used as a substrate by adenylate cyclase but not by 
protein kinases, replaced ATP in the incubation 
mixture of TPA + Ca2+ + phosphatidylserine (as 
in the legend to fig.2). 
We propose that TPA exerts its effect on 
adenylate cyclase through activation of protein 
kinase C. The site at which protein kinase C exerts 
its effect is possibly the guanine nucleotide 
regulatory protein (NJ which is involved in cyclase 
activation. This is a dimeric molecule consisting of 
an Mr 35 000 &subunit and an M, 42000 a-subunit 
which both could presumably form targets for the 
41 
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action of protein kinase C. In this respect one of 
the subunits of the GTP-binding protein, 
eukaryotic initiation factor 2, has been shown to 
be phosphorylated by protein kinase C [25]. Also, 
TPA has been demonstrated to phosphorylate an 
A.6 42000 protein in a number of cell types [26,27], 
This action of TPA may lend insight into certain 
of the molecular mechanisms involved in tumour 
promotion, and may aIso identify a novel mode of 
regulation of adenylate cyclase. 
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